Bioaegis Therapeutics Inc
CAGE Code: 6QA91
NCAGE Code: 6QA91
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 071424047
Summary
Bioaegis Therapeutics Inc is an Active Commercial Supplier with the Cage Code 6QA91 and is tracked by Dun & Bradstreet under DUNS Number 071424047..
Address
6 E Cove Ln
Morristown NJ 07960-2700
United States
Points of Contact
Related Information
People who viewed this 'CAGE Code' also viewed...
Professional Fireplace & Chimney Dusenbery Engineering Co Scott Rob Enterprises Inc Mcalpin Elizabeth Inc Par Corporation Inc. Lonza Llc Allied-Signal Inc At And T World Services Inc Pro Form Technologies Inc Quality Air Products And Services Sovereign Transportation General Photo Products Co Morristown Battery Inc Louis Berger Group (Domestic), Inc., Secrets Intl Inc Network Management Forum Inc Tel-A-Runner Inc Business Communications Group Package Development Products Inc Covanta Energy, Llc
Frequently Asked Questions (FAQ) for CAGE 6QA91
- What is CAGE Code 6QA91?
- 6QA91 is the unique identifier used by NATO Organizations to reference the physical entity known as Bioaegis Therapeutics Inc located at 6 E Cove Ln, Morristown NJ 07960-2700, United States.
- Who is CAGE Code 6QA91?
- 6QA91 refers to Bioaegis Therapeutics Inc located at 6 E Cove Ln, Morristown NJ 07960-2700, United States.
- Where is CAGE Code 6QA91 Located?
- CAGE Code 6QA91 is located in Morristown, NJ, USA.
Contracting History for CAGE 6QA91 Most Recent 25 Records
- 75A50123C00067
- Bioaegis: Plasma Gelsolin (Pgsn), An Abundant, Circulating Protein Modulates Inflammation While Also Enhancing Host Defenses By Stimulating The Uptake And Killing Of Pathogens. Clinical Studies Have Consistently Shown Pgsn Is Depleted In Severe I
- 21 Sep 2023
- Bioaegis: Plasma Gelsolin (Pgsn), An Abundant, Circulating Protein Modulates Inflammation While Also Enhancing Host Defenses By Stimulating The Uptake And Killing Of Pathogens. Clinical Studies Have Consistently Shown Pgsn Is Depleted In Severe I
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $20,000,000.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00060
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- 1 Nov 2021
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $749,000.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00060
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- 6 Oct 2022
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $749,000.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00060
- Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- 11 Jun 2021
- Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $749,000.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00060
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- 10 Feb 2022
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $749,000.00
- Department Of Health And Human Services (Hhs)
- 75A50121C00060
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- 25 Aug 2022
- Eo14042 Develop A Safe And Effective Therapeutic To Mitigate Severe Outcomes, Including But Not Limited To Mortality, In Patients With Severe Infection Or Sepsis Of Any Etiology.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $749,000.00
- Department Of Health And Human Services (Hhs)